Corcept Therapeutics stock is trading -23.47% below its average target price of $88.25 after marking a 9.8% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $67.0 to $130.0 per share.
Corcept Therapeutics has an elevated short interest of 21.8%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 20.47. Since 11.52% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. 84.9% of Corcept Therapeutics shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Corcept Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 15% | 16,050,402 | $1,084,044,165 |
| 2024-09-30 | Vanguard Group Inc | 10% | 10,006,330 | $675,827,537 |
| 2024-12-31 | Ingalls & Snyder | 8% | 8,099,747 | $547,056,919 |
| 2024-09-30 | Renaissance Technologies, LLC | 6% | 6,509,002 | $439,618,001 |
| 2024-09-30 | Parallel Advisors, LLC | 4% | 3,813,724 | $257,578,922 |
| 2024-09-30 | State Street Corporation | 3% | 3,519,263 | $237,691,026 |
| 2024-09-30 | Dimensional Fund Advisors LP | 2% | 2,532,499 | $171,044,984 |
| 2024-09-30 | Novo Holdings A/S | 2% | 2,411,362 | $162,863,391 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 2,378,758 | $160,661,317 |
| 2024-09-30 | Arrowstreet Capital, Limited Partnership | 2% | 1,580,621 | $106,755,143 |
For these reasons, we consider that the Corcept Therapeutics is the subject of positive market sentiment.
